Episode 473
A Mother’s Perspective on Childhood Cancer: Bethan Keall
Today’s Raise the Line guest has a simple but powerful message for medical providers, born of a mother’s heartbreak. “It's going to be rare in your career to meet a zebra but the impact you can have is phenomenal. An early diagnosis could make the difference between life and death for these children,” says Bethan Keall who lost her young daughter Matilda (Tilly) in 2022 to neuroblastoma, a rare cancer most commonly found in children. Because some symptoms of the disease can be easily attributed to other causes, early diagnosis is difficult, particularly if providers are not on the lookout for it. Tilly’s diagnosis of an aggressive form of neuroblastoma introduced Bethan and her husband to the unfortunate realities of a lack of funding and coordination in the UK around pediatric oncology. “For childhood cancer you really need as much collaboration among doctors as possible to understand how treatments can get better because there are relatively few cases,” she explains to host Lindsey Smith. In coping with Tilly’s tragic death at the age of four, her parents have dedicated themselves to Neuroblastoma UK to support research efforts and have benefitted from the emotional and social support provided by a charity called Jak’s Den, founded by the family of a victim of childhood cancer. This is a wrenching, illuminating episode in our Year of the Zebra series offering important insights from a parent’s perspective for providers and policymakers alike. Mentioned in this episode: Jak’s Den https://www.teamjak.org.uk/ Neuroblastoma UK https://www.neuroblastoma.org.uk/
Transcript
Lindsey Smith: Hi, I'm Lindsey Smith welcoming you to Raise the Line with Osmosis from Elsevier, an ongoing exploration about how to improve health and healthcare.
In 2023, our Year of the Zebra initiative featured the inspiring stories of many patients and families battling rare diseases, and we're happy to say we'll be continuing to raise awareness of this critical aspect of healthcare in 2024. We're kicking that off today by turning to the story of an Elsevier colleague based in the UK, Bethan Keall, who tragically lost her daughter Matilda at the age of four to neuroblastoma, a rare cancer of the sympathetic nervous system that is most common in children.
Since Matilda's passing in 2022, Bethan and her husband have dedicated themselves to Neuroblastoma UK to support research into this devastating disease. On behalf of the entire Elsevier and Osmosis team, we extend our deepest condolences to you, Bethan. We are truly sorry for your loss, and we thank you for joining us today and graciously sharing Matilda's story with us. Thank you for being here.
Bethan: Thank you, Lindsey. Nice to be here.
Lindsey: So we want to just open up by learning a little bit more about Matilda, who I understand went by Tilly for short. Can you just tell us a little bit about her?
Bethan: So, Tilly was a very happy, healthy child as I thought. She had just started nursery school in September of 2021, which was lovely. She just ran in and really enjoyed it from the very start. She just loved seeing her friends. But then she started to get sick and she was tired. She didn't want to eat. I think she did actually have “raccoon eyes” looking back on it, but at the time we didn't know what raccoon eyes were. We had no idea. All that means is that she had dark circles under her eyes, but we just thought she was tired.
Lindsey: And I think a lot of the symptoms and maybe some of those early warning signs could also be attributed to something else, right?
Bethan: Exactly. Yeah. So the loss of appetite, the tiredness… your go-to answer is not cancer. It just isn't, because it's so unusual. There are 100 children in the UK a year who get neuroblastoma. And to be fair, I had never heard of neuroblastoma before. Childhood cancer just is not well represented across the world, I don't think, to be honest. I mean in the UK, it gets a tiny, tiny proportion of funding, which is just devastating because if you can save a child's life, the value add that you get from that, because they then may live until they're eighty potentially -- and I'm not saying that you shouldn't treat other cancers or raise money for other cancers -- but the potential to add life to these children is huge. But there's just not enough funding for the research.
And the funding is tricky, as I understand it, because the UK went through Brexit, so we are more isolated, whereas childhood cancer needs connection. You need doctors to be connecting to talk about cases because there are so few cases overall. So, if you can link up with Europe or if the whole of the US can do a study, it's far more impactful than if one doctor in Scotland on their own does it. I'm based in Edinburgh and therefore that's why I use the example in Scotland.
This was explained to me by one of the doctors who'd worked in this pediatric oncology area for years and it was his frustration that for childhood cancer you need as much collaboration as possible to understand how the treatments can get better. And for that you need political will and crossing over of understanding what is the most important thing, which is the children's health.
Unfortunately, I think that gets beaten down by practicalities and politics and money and there are too many barriers in the way, I think. It makes it really challenging to find funding and find better treatments because a lot of the pediatric oncology treatments for children, are just based on adult schemes of care, essentially, which is really brutal for a three-year-old.
Lindsey: Right. Yeah. I think that's really insightful. So, you start getting these warning signs for Tilly, she's getting sick, and then you finally get to the diagnosis, which was hard to get to. Can you take us through that process of getting to the diagnosis and then the treatment and that journey?
Bethan: Yeah, so we took Tilly quite a few times because we were worried about these different symptoms and she was diagnosed by our local doctors with irritable hip. Essentially, we thought it had gone away for a bit, but actually it hadn't. I think she just got better at dealing with the pain because it was her stomach that was hurting, but she couldn't tell us that she was so tiny. Her hip was hurting because the cancer was in her bones, so she was limping. So we took her in. She was diagnosed with irritable hip.
She was also taken to A&E where they thought it was irritable hip as well, I think, or there weren't enough flags to send her for a scan, which would've told us immediately what was wrong with her. But we went back eventually to A&E and finally did get the scan and then were told what they thought was wrong, but they could only narrow it down to two things. They said it's either neuroblastoma or Wilms disease, neither of which is good, but out of the two, probably neuroblastoma is the worst.
Lindsey: Right. Can you take us through the treatments that you guys tried through this experience?
Bethan: Yeah, so this is the bit that gets really technical and I'm not the best person, but there are lots of protocols that the children are treated under. We had specific protocols that our consultant oncologist selected for Tilly based on the fact that she had the complicated and high risk side of neuroblastoma which is actually in Osmosis from Elsevier's explanation of neuroblastoma. So it's the high risk type of neuroblastoma that Matilda had, and it meant she had to have specific protocols.
It essentially meant that we had to fight it with as much chemotherapy as we could because what you need to do is get rid of the cancer so that you can then operate to take away the tumor. And then the idea is then you go through immunotherapy, I think….so this is where it gets unclear to me because Matilda actually died before she got to that bit, which is really unusual. The next part of the process is that she would've basically been in isolation. She did have her stem cells removed and they would've been replaced. So what they do is they get rid of the cancer, they take the stem cells out when there's no cancer, they store them and then they put them back in after she's had radiotherapy, I think. But because we never got to that stage, it's not that well ingrained in my psyche because she died.
It's quite unusual for the child to die before they've had that treatment. In all the cases that our oncologist had dealt with, only two children died after they took the tumor out, and Matilda was one of them, so we only had her fighting for 10 months.
But what is devastating about neuroblastoma is the fact that you are disabled for the rest of your life effectively, because you no longer have fertility; you probably have really terrible teeth because the chemotherapy wrecks the kind of growth that the teeth go through; you will have lifelong impacts of radiography and chemotherapy. So, even if she had survived, she would've constantly been looking over her shoulder, which is really scary. It's bad enough going through it once, but we have been linked up with families who thought their child was in remission, and then it came back.
Once neuroblastoma comes back for a second time, it's pretty much game over. You've got a 5% chance of survival. So when you are first diagnosed, often you've got a 50% chance of survival, but when you have the high risk type of neuroblastoma, that reduces even further. And then if you relapse at any point from neuroblastoma, if it comes back, there's nothing else that they have to fight it with and that's why there needs to be more research. That's why we need to find a way of tackling this at the start.
There's quite a lot of really interesting work being done in the US. So, a conversation I had with my oncologist -- because I work for Elsevier and I looked up the studies -- is that there's groundbreaking work being done in the US…almost like a vaccine for neuroblastoma to stop it coming back. But I think the cost of that, if you were coming from the UK, is something like $750,000 (US) which is just massive. I mean, people fundraise in the UK to be able to go and do it to save their child's life, but it has massive financial implications for the family for the rest of time, unless they can fundraise. So, do you fund it by remortgaging? Yes, everybody raises funds, but $750,000 is a huge amount to find. When we were doing it, I think there were two other children at the same time who were wanting to do this. So you are fundraising in quite a small area for three children for $750,000 each. It's just really hard. But you'll do anything to give your child the best chance of survival,
Lindsey: Right. Absolutely. Absolutely. So it sounds like there are some treatments in the pipeline, but still some barriers to entry on that with the costs.
Bethan: Yeah, exactly.
Lindsey: I want to come back to something you said earlier about community, and it sounds like you've made some connections with other parents. Can you talk a little bit about the community that you've made that maybe helped you through this experience?
Bethan: So, we're very lucky to have a wonderful charity called Jak’s Den. They are a wonderful charity run by a wonderful woman called Allison Barr. Her child died of cancer in his late teens and before he died, he said to his mom that it would be really good if you set up something so that cancer survivors can come together and meet each other and bereaved families can be supported in their journey. And that's exactly what she did. She's done an amazing thing in Scotland and brought lots of people together. I've met lots of families who've had a very similar path to ours, which is reassuring because when you go through struggles and nobody can really understand… you can ask. There are other families who have experienced the loss that you have.
And also there are some families who with losing a child, lose their whole family. I'm very lucky to have another child called Emily, but without her, I think it would've been very difficult to find the purpose in life to carry on. I know my purpose is to make sure Emily doesn't suffer too much over the loss of her sister because they were very close. But if that's your only child and that reason goes…I find it very difficult to understand how you would get through that. I mean, it's hard enough when you've got a child to kind of focus yourself on, but when you haven't got that….people do amazing things with that. But I think they're phenomenally strong to be able to do that.
Lindsey: Yeah, no question about that. I'm glad that you have that community to lean on during these times. Another community that I believe you're involved in neuroblastoma UK.
Bethan: Yes, that's right. So Jak’s Den does the kind of social side for us and Neuroblastoma UK does the really critical side, which is raising funds to try and get better treatments for neuroblastoma itself. We have raised funds. Emily does dance and Matilda did dance and Mhairi Hogg School of Dancing very kindly raise a loss of money for neuroblastoma the UK. It's a brilliant charity, but it's tiny because so few people are touched by this dreadful illness. I mean, thank goodness there aren't very many, but it's difficult to get funding for or small pockets of childhood pediatric cancer because they don't have the voices to go to Parliament and argue for things. We have to do that for them. And also, it's not one type of childhood cancer. There are brain tumors, there is neuroblastoma, there's lots of different types.
When you've got the kind of massive causes like breast cancer or prostate cancer for adults, the number of people that this touches are enormous. Most people know somebody in their lives who's been touched by either breast cancer or prostate cancer. I would say the odds are a family or a friend has been affected by these issues. It's very rare to find somebody affected by pediatric cancer because it doesn't happen a lot, thank goodness. But it makes fundraising really difficult because it's in small pockets essentially. And it is critical to raise funds for childhood cancer because like I said at the start, you can add sixty or seventy years to somebody's life if you are able to help them survive. And that's huge.
Lindsey: Absolutely. So how can our listeners get more involved?
Bethan: That's a really good question. I mean, I think educating yourselves about the symptoms and understanding that the most obvious choice is the routine ‘the child's got a virus’ but always at the back of your mind, keeping in your focus the fact that there could be something far more sinister at work and thinking that an early diagnosis could make the difference between life and death for these children.
So, I guess for the listeners who are in medical positions themselves, it is understanding that it's going to be rare in your career to meet a zebra, but the impact you can have on that zebra with a rare disease is phenomenal because you could pick up something at a stage where it's much more treatable than it would be much further down the road. Essentially, that is why diagnosis for things like neuroblastoma is so tricky because it can be mistaken for lots of other much less serious illnesses.
Lindsey: Very well said there, and I think that ties in really nicely with the whole concept of the Year of the Zebra, and why we are trying to get these rare disease conditions in front of our audience of future healthcare professionals and expose them to the zebras and not the horses, so that when they do come across these zebras, we hope it helps improve patient outcomes. We hope that it improves the time to get diagnosed with these rare diseases. Right now it's around four to seven years typically to get a proper diagnosis, so we are hoping the Year of the Zebra plays a small part in helping with these rare disease patients.
Before we close out Bethan, is there anything else you'd like to share with our audience of future healthcare professionals or anything else you'd like them to understand about families of children with rare diseases?
Bethan: The only time that I found the treatment of Matilda really difficult is when I had an anesthetist tell me that they understood what I was going through. I found the whole interaction really difficult. I think unless you have had a child who is suffering from a disease that could take their life, you do not understand. And the healthcare professional said to me, “But the thing is, I've been trained in this. This is what I do.” And I'm like, there's such a world difference between being trained in something and living as a parent with a child who has a disease that's life limiting.
So, just be aware that you can empathize and you can be very sensitive -- and that is very important -- but never say you understand exactly what they're going through because you just can't until it happens to you. I had no idea what it would be like.
Lindsey: Thank you for sharing that takeaway with our audience, and thank you for being here, Bethan, and sharing the story of Tilly with us.
Bethan: Thank you, Lindsey.
Lindsey: I'm Lindsey Smith. Thanks for checking out today's show. Remember to do your part to raise the line and strengthen our healthcare systems. We're all in this together.